Comparison of effectiveness of sirolimus-eluting stents versus bare metal stents for percutaneous coronary intervention in patients at high risk for coronary restenosis or clinical adverse events

American Journal of Cardiology

Volumn 95, Issue 12, 2005, Pages 1409-1414

  Marzocchi, Antonio ^a   Piovaccari, Giancarlo ^b   Manari, Antonio ^b   Aurier, Enrico ^b   Benassi, Alberto ^b   Saia, Francesco ^b   Casella, Gianni ^b   Varani, Elisabetta ^b   Santarelli, Andrea ^b   Guastaroba, Paolo ^b   Grilli, Roberto ^b   Maresta, Aleardo ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; METAL; RAPAMYCIN; TICLOPIDINE;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DRUG EFFECT; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTENOSIS; SCORING SYSTEM; SIDE EFFECT; STENT;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; METALS; MIDDLE AGED; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SIROLIMUS; STENTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 20444469536     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.01.096     Document Type: Article

References (8)

1. S.J. Brener, F.D. Loop, B.W. Lytle, S.G. Ellis, D.M. Cosgrove, E.J. Topol A profile of candidates for repeat myocardial revascularization implications for selection of treatment J Thorac Cardiovasc Surg 114 1997 153 161
2. R.B. D'Agostino Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 1998 2265 2281
3. M.E. Charlson, P. Pompei, K.L. Ales, C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies development and validation J Chron Dis 40 1987 373 383
4. P.S. Romano, L.L. Roos, J.G. Jollis Adapting a clinical comorbidity index for use with ICD-9-CM administrative data differing perspectives J Clin Epidemiol 46 1993 1075 1079
5. M.C. Morice, P.W. Serruys, J.E. Sousa, J. Fajadet, E. Ban Hayashi, M. Perin, A. Colombo, G. Schuler, P. Barragan, G. Guagliumi A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
6. J.W. Moses, M.B. Leon, J.J. Popma, P.J. Fitzgerald, D.R. Holmes, C. O'Shaughnessy, R.P. Caputo, D.J. Kereiakes, D.O. Williams, P.S. Teirstein Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
7. J. Schofer, M. Schluter, A.H. Gershlick, W. Wijns, E. Garcia, E. Schampaert, G. Breithardt Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries double-blind, randomised controlled trial (E-SIRIUS) Lancet 362 2003 1093 1099
8. P.A. Lemos, P.W. Serruys, R.T. Van Domburg, F. Saia, C.A. Arampatzis, A. Hoye, M. Degertekin, K. Tanabe, J. Daemen, T.K. Liu Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world." The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry Circulation 109 2004 190 195